Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Trastuzumab Pamirtecan in HER2-Expressing Endometrial Carcinoma: NCT06340568 Clinical Landscape Report 2026
16 October 2026
NCT06340568 clinical landscape for HER2-Expressing Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
CD19-CAR-DNT Cells in Systemic Lupus Erythematosus: NCT06340490 Clinical Landscape Report 2026
16 October 2026
NCT06340490 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Irinotecan Hydrochloride Lioposome in Ewing Sarcoma: NCT06340204 Clinical Landscape Report 2026
16 October 2026
NCT06340204 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Recurrent Follicular Lymphoma: NCT06343376 Clinical Landscape Report 2026
16 October 2026
NCT06343376 clinical landscape for Recurrent Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zorpocabtagene autoleucel in Dermatomyositis: NCT06347718 Clinical Landscape Report 2026
16 October 2026
NCT06347718 clinical landscape for Dermatomyositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Metastatic breast cancer: NCT06342037 Clinical Landscape Report 2026
16 October 2026
NCT06342037 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Naporafenib in NRAS Mutant Melanoma: NCT06346067 Clinical Landscape Report 2026
16 October 2026
NCT06346067 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Recurrent Triple-Negative Breast Carcinoma: NCT06347068 Clinical Landscape Report 2026
16 October 2026
NCT06347068 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Cabozantinib (s)-Malate in Osteosarcoma: NCT06341712 Clinical Landscape Report 2026
16 October 2026
NCT06341712 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19-BAFF Targeted CAR T-cells(Yake Biotechnology) in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: NCT06346912 Clinical Landscape Report 2026
16 October 2026
NCT06346912 clinical landscape for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset conte…
9 min read
CD19/BCMA CAR-T Cell(Wuhan Union Hospital) in Systemic Lupus Erythematosus: NCT06349343 Clinical Landscape Report 2026
16 October 2026
NCT06349343 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/BCMA-CAR-T cells(Essen Biotech) in Idiopathic Inflammatory Myopathies: NCT06350110 Clinical Landscape Report 2026
16 October 2026
NCT06350110 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…